Xiang-Yong Hao

Lanzhou University, Kao-lan-hsien, Gansu Sheng, China

Are you Xiang-Yong Hao?

Claim your profile

Publications (2)5.53 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the effectiveness of octreotide in advanced hepatocellular carcinoma participants on the basis of randomized controlled trials. We searched the Cochrane Center Register of Controlled Trials in The Cochrane Library, PubMed, EMBASE, Chinese Biomedical Literature Database, China Journal Full-text Database, Chinese Scientific Journals Database up to June 2008 in any language. Randomized controlled trials of octreotide for advanced hepatocellular carcinoma were selected and evaluated by two investigators. Any disagreement was solved by discussion. Analyses were performed using Review Manager 4.2. Six randomized controlled trials totaling 352 participants were included. The median survival time was reported in four randomized controlled trials. The results between the octreotide group and the control group (the placebo or best supportive care group) were as follows: 13.0 versus 4.0 months, 1.93 versus 1.97 months, 4.7 versus 5.3 months, and 7.0 versus 2.5 months. Three randomized controlled trials reported 6-month survival rates and 12-month survival rates and meta-analysis results in these two outcomes [(RR 1.35, 95% CI 0.92-1.97); (RR 1.35, 95% CI 0.66-11.16) respectively] were not found to be statistically significant by random-effects model. When we analyzed 6-month survival rates by fixed-effect model (RR 1.30, 95% CI 1.02-1.66), meta-analysis result reached statistical significance. As for the limitations of the included trials, the result may not demonstrate a significant superiority of octreotide administration in participants with advanced hepatocellular carcinoma from the available evidence.
    Full-text · Article · Jul 2009 · Journal of Cancer Research and Clinical Oncology
  • Xiang-Yong Hao · Ke-Hu Yang · Tian-Kang Guo · Bin Ma · Jin-Hui Tian · Hong-Ling Li
    [Show abstract] [Hide abstract]
    ABSTRACT: Whether omentoplasty after colorectal anastomosis can reduce anastomotic leakage is controversial. Our aim was to do a meta-analysis of randomized controlled trials to compare anastomotic leakage rates between an omentoplasty group and a no omentoplasty group after colorectal anastomosis. We searched the Cochrane Center Register of Controlled Trials, PubMed, EMBASE, and Chinese Biomedical Literature Database up to June 2008 in any language. Reference lists from all selected articles were also examined. Randomized controlled trials of omentoplasty in the prevention of anastomotic leakage after colorectal resection were selected and evaluated by two investigators. Analyses were performed using Review Manager 4.2. Three randomized controlled trials totaling 943 participants were included. Meta-analysis results showed that no statistically significant difference was found between the omentoplasty group and the no omentoplasty group in radiological anastomotic leakage (RR 0.76, 95% CI 0.41 to 1.40), death (RR 1.01, 95% CI 0.55 to 1.86), and repeat operation (RR 0.60, 95% CI 0.35 to 1.05), except for clinical anastomotic leakage (RR 0.36, 95% CI 0.16 to 0.78). Based on available data from a small number of trials, there is not enough evidence to say whether or not omentoplasty should be used to reduce anastomotic leakage after colorectal resection. The decision as to whether we should continue to use this technique might remain a matter of surgical judgment. Therefore, the results still need to be confirmed by future multicenter, well-designed trials.
    No preview · Article · Oct 2008 · International Journal of Colorectal Disease